:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/2LT5UESFVRP3FKEHOCH7A2FGYE.jpg)
El Hospital de Fuenlabrada lidera un ensayo clínico para aumentar la supervivencia con cáncer de colón
En concreto es para tratamiento de metástasis peritoneales, que hasta hace poco se consideraban “incurables”
Ensayos clínicos
:quality(70):focal(2114x994:2124x1004)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/BAZA2ELB35EMVGTTLIGAB2L4CA.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/UMPU43SORBHCXM4NJFGX4OW7FA.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/M3K4WHTIWBCM5CPL3EFGT35OOI.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/KJCL6Y47AZAYHNCU3ZWLAR7W3A.jpg)
:quality(70):focal(474x305:484x315)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/6QNJRAUZ75MATAESOMTBAKY7KI.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/AEKX7R6SEZAO7DJMWEH2X2BZ2M.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/CVBJJG5MSRKUBA2KFHTBTLU6QE.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/IX6BMXLGNVN57IY3LUIVDPWACM.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/XPGYJHGALZONVAN67R4CSMNZRY.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/JWNZYOFBPBMURGJJCIONB2URJY.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/LNBRENLRQNLT7OUPPJNJNAD4LI.jpg)
CORONAVIRUS FÁRMACOS (Actualización)
La farmacéutica Grífols probará un medicamento que puede dar inmunidad inmediata contra la COVID-19
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/36RHQMZZYJNZTMISE2642ZBKRA.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/4M6XQJ7MQBLZFJ5OMI2TV74YKQ.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/IDB3J2LHOVJJ3GSLX6ES2AI3C4.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/SJADLMEMHRJSHASQAGIQWDKYV4.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/ZOYZNWDMPNKSBOCUITIDU6D4AU.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/Q6TB2LV5EZISFEV5GQAD4JK5RM.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/FNL3ABAOMZL3ZID4B2WQKKEDFY.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/Y6BCRQD4P5PPBKDBW7BWPC2ACM.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/KMY4WSL57VLGZKBGOE2LM2Z7RA.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/PCLZVIJ3RNIDPFSKC7F4IWUA2A.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/F6RI7EYOTBNYBPU73BPTB37OEY.jpg)
:quality(70)/cloudfront-eu-central-1.images.arcpublishing.com/prisaradio/KQLFLUM2EFNWPGQSOKQKGVJWVE.jpg)
